Will an activist investor boost the GlaxoSmithKline share price?

The GlaxoSmithKline share price is struggling. But Andy Ross asks: could it get a boost from the arrival of Elliott, an activist investor?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price has struggled for the past 18 months or so. This has heaped pressure on management and attracted the attention of activist investors. Last month it was reported that one such, Elliott, had taken a stake. 

This investment follows a string of disappointments at the company and its subsequent share price decline. Over the last 12 months, the shares have fallen 17%. By comparison, rival AstraZeneca’s share price is down by only 9%, despite its high-profile clashes with the EU over Covid vaccines. I’d think that would mean its share price performance should be worse, indicating just how out of favour GlaxoSmithKline shares are.

What’s gone wrong at GlaxoSmithKline?

My perception is that GlaxoSmithKline is playing catch-up with other leading pharma groups to replenish its pipeline of blockbuster drugs. The journey to new drugs is far from plain sailing. In January, cancer hopeful bintrafusp alfa failed a key late-stage trial. Another drug in the company’s oncology pipeline, dostarlimab, suffered an inspection delay.

Overall, the company is paying the price for being much slower to invest in its research than competitors. In turn, this means there’s a perception it’s overpaying to acquire growth, for example through the £4bn acquisition of Tesaro.

Developing new drugs takes a long time. It seems investors are losing patience with GlaxoSmithKline, as competitors continue to pull ahead.

The fact that GSK is a major vaccine developer, but has struggled so far to create an effective Covid-19 vaccine, won’t have helped its image.

Can Elliott boost the GlaxoSmithKline share price?

It’s not clear yet what Elliott intends to do so it’s hard to say whether it can boost the GSK share price. Elliott has a mixed record of agitating for change at other pharmaceutical groups. At GlaxoSmithKline, its job may be made easier by the fact that other major investors seem to be losing faith in management and will want to see the share price performance improve.

Part of Elliott’s ability to force through change at GSK will depend upon how other investors react to its proposals – once they’re known.

It’s far from guaranteed that the activist investors’ involvement will benefit private investors, or that the change they want to see will happen. For example, Barclays managed to see off Sherborne Investors, which had been agitating for the firm to get rid of its investment bank. 

Would I add it to my portfolio?

It could be argued that GlaxoSmithKline is a cheap recovery share that provides quite a generous level of income. The dividend yield is 5.8%. The fact that expectations are low means GSK could outperform. A run of positive drug trial updates has the potential to really boost the GlaxoSmithKline share price. That’s the positive view. But I’m not tempted to add it to my portfolio. The planned spin-out of its consumer business will make it even more reliant on its new drug pipeline and scientists. Both of these seem to be underperforming. I’d therefore be quite worried about the dividend in the future and about whether the share price will improve.

I’ll avoid it for my portfolio. I think there’s a very real risk that the GlaxoSmithKline share price could keep heading down over the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross owns shares in AstraZeneca. The Motley Fool UK has recommended Barclays and GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »